These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28392127)

  • 1. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
    Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
    Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
    Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
    Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
    Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
    Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
    Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
    Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
    Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.
    Baia GS; Caballero OL; Ho JS; Zhao Q; Cohen T; Binder ZA; Salmasi V; Gallia GL; Quinones-Hinojosa A; Olivi A; Brem H; Burger P; Strausberg RL; Simpson AJ; Eberhart CG; Riggins GJ
    Cancer Immunol Res; 2013 Nov; 1(5):296-302. PubMed ID: 24777967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
    Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
    Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma].
    Wu XJ; Wang Y; Ji JF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):252-6. PubMed ID: 15968313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
    Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
    Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.